L
US$ 21.89
bpc-157 clinical studies BPC-157 Clinical Trials Planned by
Description
Sikiric is listed as the CEO of a company called Diagen, which holds patents for what it describes as a "special stable version" of BPC-157
Daarom accepteren wij geen batches onder de 99%-grens voor beide individuele componenten
some early nausea
These are exciting prospects that could revolutionize how we approach metabolic studies
they're embarking on a journey tailored specifically for them
